Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$4.08
-1.3%		$3.39
$2.77
▼
$7.18
$2.18B1.0718.34 million shs11.10 million shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$30.46
-1.9%		$20.80
$10.94
▼
$32.45
$2.25B1.691.45 million shs3.39 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+2.48%+11.62%+21.47%+8.68%-15.37%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
+2.37%+6.23%+59.23%+83.95%+54.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$4.08
-1.3%		$3.39
$2.77
▼
$7.18
$2.18B1.0718.34 million shs11.10 million shs
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$30.46
-1.9%		$20.80
$10.94
▼
$32.45
$2.25B1.691.45 million shs3.39 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
+2.48%+11.62%+21.47%+8.68%-15.37%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
+2.37%+6.23%+59.23%+83.95%+54.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2.20
Hold$8.0698.28% Upside
Schrodinger, Inc. stock logo
SDGR
Schrodinger
2.33
Hold$20.80-33.93% Downside

Current Analyst Ratings Breakdown

Latest SDGR and RXRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/17/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$5.30
8/14/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$13.00 ➝ $19.00
8/14/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$13.00 ➝ $19.00
8/12/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/29/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/15/2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
$74.68M29.14N/AN/A$2.14 per share1.90
Schrodinger, Inc. stock logo
SDGR
Schrodinger
$255.87M9.08N/AN/A$4.94 per share6.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$644.76M-$1.04N/AN/AN/A-945.94%-50.41%-38.25%11/4/2026 (Estimated)
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$103.26M-$0.74N/AN/AN/A-20.98%-16.37%-8.19%11/4/2026 (Estimated)

Latest SDGR and RXRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
-$0.24-$0.25-$0.01-$0.25$10.97 million$7.67 million
8/5/2026Q2 2026
Schrodinger, Inc. stock logo
SDGR
Schrodinger
-$0.4145$0.08+$0.4945$0.08$47.19 million$58.89 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
N/AN/AN/AN/AN/A
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
0.01
5.03
5.03
Schrodinger, Inc. stock logo
SDGR
Schrodinger
N/A
2.71
2.71

Institutional Ownership

CompanyInstitutional Ownership
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
89.06%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
79.05%

Insider Ownership

CompanyInsider Ownership
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
6.65%
Schrodinger, Inc. stock logo
SDGR
Schrodinger
10.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
600535.34 million499.74 millionOptionable
Schrodinger, Inc. stock logo
SDGR
Schrodinger
85073.82 million66.37 millionOptionable

Recent News About These Companies

Schrodinger (NASDAQ:SDGR) Reaches New 12-Month High - Should You Buy?
September 30 at 12:20 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-schrodinger-nasdaq-sdgr-reaches-new-12-month-high-should-you-buy-2026-09-30/
Bank of America Corp DE Makes New $2.94 Million Investment in Schrodinger, Inc. $SDGR
September 30 at 3:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-makes-new-294-million-investment-in-schrodinger-inc-sdgr-2026-09-30/
Schrödinger (SDGR) Could Be 29% Below Fair Value Despite A 38% Overvalued View
September 27, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/schr-dinger-sdgr-could-29-200558709.html
Schrodinger Stock Has Technical Strength as It Hits New 2-Year Highs
September 23, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/schrodinger-stock-technical-strength-hits-175003541.html
Karen Akinsanya Sells 31,599 Shares of Schrodinger (NASDAQ:SDGR) Stock
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31041859
Schrodinger (NASDAQ:SDGR) Insider Karen Akinsanya Sells 31,599 Shares
September 22, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-sdgr-insider-buying-and-selling-2026-09-22/
Schrodinger (NASDAQ:SDGR) Insider Sells $928,062.63 in Stock
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-schrodinger-nasdaq-sdgr-insider-sells-92806263-in-stock-2026-09-21/
Schrodinger (NASDAQ:SDGR) Hits New 12-Month High - Here's What Happened
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-schrodinger-nasdaq-sdgr-hits-new-12-month-high-heres-what-happened-2026-09-21/
Engineers Gate Manager LP Decreases Stock Holdings in Schrodinger, Inc. $SDGR
September 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-engineers-gate-manager-lp-decreases-stock-holdings-in-schrodinger-inc-sdgr-2026-09-21/
Schrödinger, Inc. Partners with NEA and RA Capital Management to Co-Found Tectora
September 19, 2026  |  labroots.comL
Schrodinger, Inc. (NASDAQ:SDGR) Receives Average Rating of "Hold" from Analysts
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-schrodinger-inc-nasdaq-sdgr-receives-average-rating-of-hold-from-analysts-2026-09-19/
Why DataMEDS’ acquisition does not seem to be very bullish for MEDS stock at this point
September 18, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/why-datameds-acquisition-does-not-seem-to-be-very-bullish-for-meds-stock-at-this-point/ar-AA2cxeSl
Schrodinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
September 18, 2026  |  marketscreener.comM
Schrodinger (NASDAQ:SDGR) Sees Unusually-High Trading Volume - Still a Buy?
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-schrodinger-nasdaq-sdgr-sees-unusually-high-trading-volume-still-a-buy-2026-09-17/
Schrödinger: Company Creation Is Now The Real Drug Business
September 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947506-schrodinger-company-creation-is-now-the-real-drug-business
Traders Buy High Volume of Schrodinger Call Options (NASDAQ:SDGR)
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-traders-buy-high-volume-of-schrodinger-call-options-nasdaq-sdgr-2026-09-17/
Schrödinger, Inc. (SDGR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 16, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4947046-schrodinger-inc-sdgr-presents-at-morgan-stanley-24th-annual-global-healthcare-conference
Schrodinger (SDGR) Soars 12.1%: Is Further Upside Left in the Stock?
September 16, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2990339/schrodinger-sdgr-soars-12-1-is-further-upside-left-in-the-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|daily_price_change_5%-2990339
Schrödinger jumps 12% to new 52-week high amid AI drug-discovery interest
September 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4643192-schrodinger-jumps-12-percent-to-new-52-week-high-amid-ai-drug-discovery-interest
Schrodinger (NASDAQ:SDGR) Sets New 12-Month High - Still a Buy?
September 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-schrodinger-nasdaq-sdgr-sets-new-12-month-high-still-a-buy-2026-09-15/
Schrodinger (NASDAQ:SDGR) Trading 9.7% Higher - Time to Buy?
September 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-schrodinger-nasdaq-sdgr-trading-97-higher-time-to-buy-2026-09-14/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Recursion Pharmaceuticals stock logo

Recursion Pharmaceuticals NASDAQ:RXRX

$4.08 -0.06 (-1.33%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Schrodinger stock logo

Schrodinger NASDAQ:SDGR

$30.46 -0.59 (-1.90%)
As of 02:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas